Endocrinology and Metabolism

Review Article

Thyroid
Active Surveillance for Low-Risk Thyroid Cancers: A Review of Current Practice Guidelines: Min Joo Kim, Jae Hoon Moon, Eun Kyung Lee, Young Shin Song, Kyong Yeun Jung, Ji Ye Lee, Ji-hoon Kim, Kyungsik Kim, Sue K. Park, Young Joo Park; Endocrinol Metab. 2024;39(1):47-60. Published online February 15, 2024; DOI: https://doi.org/10.3803/EnM.2024.1937

2,417 View
178 Download
1 Crossref

The indolent nature and favorable outcomes associated with papillary thyroid microcarcinoma have prompted numerous prospective studies on active surveillance (AS) and its adoption as an alternative to immediate surgery in managing low-risk thyroid cancer. This article reviews the current status of AS, as outlined in various international practice guidelines. AS is typically recommended for tumors that measure 1 cm or less in diameter and do not exhibit aggressive subtypes on cytology, extrathyroidal extension, lymph node metastasis, or distant metastasis. To determine the most appropriate candidates for AS, factors such as tumor size, location, multiplicity, and ultrasound findings are considered, along with patient characteristics like medical condition, age, and family history. Moreover, shared decision-making, which includes patient-reported outcomes such as quality of life and cost-effectiveness, is essential. During AS, patients undergo regular ultrasound examinations to monitor for signs of disease progression, including tumor growth, extrathyroidal extension, or lymph node metastasis. In conclusion, while AS is a feasible and reliable approach for managing lowrisk thyroid cancer, it requires careful patient selection, effective communication for shared decision-making, standardized follow-up protocols, and a clear definition of disease progression.

Citations

Citations to this article as recorded by

2023 Update of the Korean Thyroid Association Guidelines for the Management of Thyroid Nodules
Eun Kyung Lee, Young Joo Park
Clinical Thyroidology®.2024; 36(4): 153. CrossRef

Brief Report

Diabetes, obesity and metabolism
Partial Deletion of Perk Improved High-Fat Diet-Induced Glucose Intolerance in Mice: Jooyeop Lee, Min Joo Kim, Seoil Moon, Ji Yoon Lim, Kyong Soo Park, Hye Seung Jung; Endocrinol Metab. 2023;38(6):782-787. Published online November 13, 2023; DOI: https://doi.org/10.3803/EnM.2023.1738

734 View
45 Download

Abstract PDF Supplementary Material PubReader ePub: Although pancreatic endoplasmic reticulum kinase (PERK) is indispensable to beta cells, low-dose PERK inhibitor improved glucose- stimulated insulin secretion (GSIS) and hyperglycemia in diabetic mice. Current study examined if partial deletion of Perk (Perk^+/-) recapitulated the effects of PERK inhibitor, on the contrary to the complete deletion. Perk^+/- mice and wild-type controls were fed with a high-fat diet (HFD) for 23 weeks. Glucose tolerance was evaluated along with serum insulin levels and islet morphology. Perk^+/- mice on normal chow were comparable to wild-type mice in various metabolic features. HFD-induced obesity was not influenced by Perk reduction; however, HFD-induced glucose intolerance was significantly improved since 15-week HFD. HFD-induced compromises in GSIS were relieved by Perk reduction, accompanied by reductions in phosphorylated PERK and activating transcription factor 4 (ATF4) in the islets. Meanwhile, HFD-induced islet expansion was not significantly affected. In summary, partial deletion of Perk improved glucose tolerance and GSIS impaired by diet-induced obesity, without changes in body weights or islet mass.

Corrigendum

Miscellaneous
Corrigendum: Affiliation Correction. Development and Validation of a Risk Scoring System Derived from Meta-Analyses for Papillary Thyroid Cancer: Sunghwan Suh, Tae Sik Goh, Yun Hak Kim, Sae-Ock Oh, Kyoungjune Pak, Ju Won Seok, In Joo Kim; Endocrinol Metab. 2023;38(2):287. Published online April 27, 2023; DOI: https://doi.org/10.3803/EnM.2023.202; Corrects: Endocrinol Metab 2020;35(2):435

927 View
60 Download

PDF PubReader ePub

Original Articles

Thyroid
Clinical Outcomes of Repeated Radioactive Iodine Therapy for Graves’ Disease: Min Joo Kim, Sun Wook Cho, Ye An Kim, Hoon Sung Choi, Young Joo Park, Do Joon Park, Bo Youn Cho; Endocrinol Metab. 2022;37(3):524-532. Published online June 16, 2022; DOI: https://doi.org/10.3803/EnM.2022.1418

4,871 View
231 Download
2 Web of Science
2 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Radioactive iodine (RAI) therapy is a successful therapeutic modality for Graves’ disease. However, RAI therapy can fail, and RAI therapy after antithyroid drugs (ATDs) has a lower remission rate. Therefore, many patients require repeated RAI therapy. This study investigated the clinical outcomes of repeated RAI therapy for Graves’ disease.
Methods
Patients who underwent RAI therapy as second-line therapy after failure of ATD treatment between 2001 and 2015 were reviewed. Remission was defined as hypothyroid or euthyroid status without ATD, and with or without levothyroxine at 12 months after RAI therapy.
Results
The 1-year remission rate after 2nd RAI therapy (66%, 152/230) is significantly higher than that after 1st RAI therapy (48%, 393/815) or long-term ATD treatment after 1st RAI therapy failure (42%). The clinical response to 2nd RAI therapy was more rapid. The median time intervals from the 2nd RAI therapy to ATD discontinuation (1.3 months) and to the start of levothyroxine replacement (2.5 months) were significantly shorter than those for the 1st RAI therapy. A smaller goiter size, a longer time interval between the 1st and 2nd RAI therapies, and a longer ATD discontinuation period predicted remission after the 2nd RAI therapy. Finally, in 78 patients who failed the 2nd RAI therapy, the mean ATD dosage significantly reduced 5.1 mg over 12 months.
Conclusion
Repeated RAI therapy can be a good therapeutic option, especially in patients with smaller goiters and those who are more responsive to the 1st RAI therapy.

Citations

Citations to this article as recorded by

The Early Changes in Thyroid-Stimulating Immunoglobulin Bioassay over Anti-Thyroid Drug Treatment Could Predict Prognosis of Graves’ Disease
Jin Yu, Han-Sang Baek, Chaiho Jeong, Kwanhoon Jo, Jeongmin Lee, Jeonghoon Ha, Min Hee Kim, Jungmin Lee, Dong-Jun Lim
Endocrinology and Metabolism.2023; 38(3): 338. CrossRef
Effect of liver dysfunction on outcome of radioactive iodine therapy for Graves’ disease
Yuyang Ze, Fei Shao, Xuefeng Feng, Shanmei Shen, Yan Bi, Dalong Zhu, Xiaowen Zhang
BMC Endocrine Disorders.2022;[Epub] CrossRef

Thyroid
Whole-Exome Sequencing in Papillary Microcarcinoma: Potential Early Biomarkers of Lateral Lymph Node Metastasis: Mijin Kim, Chae Hwa Kwon, Min Hee Jang, Jeong Mi Kim, Eun Heui Kim, Yun Kyung Jeon, Sang Soo Kim, Kyung-Un Choi, In Joo Kim, Meeyoung Park, Bo Hyun Kim; Endocrinol Metab. 2021;36(5):1086-1094. Published online October 28, 2021; DOI: https://doi.org/10.3803/EnM.2021.1132

3,612 View
110 Download
4 Web of Science
4 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Early identification of patients with high-risk papillary thyroid microcarcinoma (PTMC) that is likely to progress has become a critical challenge. We aimed to identify somatic mutations associated with lateral neck lymph node (LN) metastasis (N1b) in patients with PTMC.
Methods
Whole-exome sequencing (WES) of 14 PTMCs with no LN metastasis (N0) and 13 N1b PTMCs was performed using primary tumors and matched normal thyroid tissues.
Results
The mutational burden was comparable in N0 and N1b tumors, as the median number of mutations was 23 (range, 12 to 46) in N0 and 24 (range, 12 to 50) in N1b PTMC (P=0.918). The most frequent mutations were detected in PGS1, SLC4A8, DAAM2, and HELZ in N1b PTMCs alone, and the K158Q mutation in PGS1 (four patients, Fisher’s exact test P=0.041) was significantly enriched in N1b PTMCs. Based on pathway analysis, somatic mutations belonging to the receptor tyrosine kinase-RAS and NOTCH pathways were most frequently affected in N1b PTMCs. We identified four mutations that are predicted to be pathogenic in four genes based on Clinvar and Combined Annotation-Dependent Depletion score: BRAF, USH2A, CFTR, and PHIP. A missense mutation in CFTR and a nonsense mutation in PHIP were detected in N1b PTMCs only, although in one case each. BRAF mutation was detected in both N0 and N1b PTMCs.
Conclusion
This first comprehensive WES analysis of the mutational landscape of N0 and N1b PTMCs identified pathogenic genes that affect biological functions associated with the aggressive phenotype of PTMC.

Citations

Citations to this article as recorded by

What can we learn about acid-base transporters in cancer from studying somatic mutations in their genes?
Bobby White, Pawel Swietach
Pflügers Archiv - European Journal of Physiology.2024; 476(4): 673. CrossRef
Comprehensive Long-Read Sequencing Analysis Discloses the Transcriptome Features of Papillary Thyroid Microcarcinoma
Yanqiang Wang, Binbin Zou, Yanyan Zhang, Jin Zhang, Shujing Li, Bo Yu, Zhekun An, Lei Li, Siqian Cui, Yutong Zhang, Jiali Yao, Xiuzhi Shi, Jing Liu
The Journal of Clinical Endocrinology & Metabolism.2024; 109(5): 1263. CrossRef
Feasibility of whole‐exome sequencing in fine‐needle aspiration specimens of papillary thyroid microcarcinoma for the identification of novel gene mutations
Liyuan Ma, Luying Gao, Ya Hu, Xiaoyi Li, Chunhao Liu, Jiang Ji, Xinlong Shi, Aonan Pan, Yuang An, Nengwen Luo, Yu Xia, Yuxin Jiang
Clinical Genetics.2024; 105(5): 567. CrossRef
Multi-omics analysis reveals a molecular landscape of the early recurrence and early metastasis in pan-cancer
Dan-ni He, Na Wang, Xiao-Ling Wen, Xu-Hua Li, Yu Guo, Shu-heng Fu, Fei-fan Xiong, Zhe-yu Wu, Xu Zhu, Xiao-ling Gao, Zhen-zhen Wang, Hong-jiu Wang
Frontiers in Genetics.2023;[Epub] CrossRef

Thyroid
Comparison of Korean vs. American Thyroid Imaging Reporting and Data System in Malignancy Risk Assessment of Indeterminate Thyroid Nodules: Sunyoung Kang, Seul Ki Kwon, Hoon Sung Choi, Min Joo Kim, Young Joo Park, Do Joon Park, Sun Wook Cho; Endocrinol Metab. 2021;36(5):1111-1120. Published online October 21, 2021; DOI: https://doi.org/10.3803/EnM.2021.1208

4,014 View
127 Download
8 Web of Science
8 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
The management of cytologically indeterminate thyroid nodules is challenging for clinicians. This study aimed to compare the diagnostic performance of the Korean Thyroid Imaging Reporting and Data Systems (K-TIRADS) with that of the American College of Radiology (ACR)-TIRADS for predicting the malignancy risk of indeterminate thyroid nodules.
Methods
Thyroid nodules diagnosed by fine-needle aspiration (FNA) followed by surgery or core needle biopsy at a single referral hospital were enrolled.
Results
Among 200 thyroid nodules, 78 (39.0%) nodules were classified as indeterminate by FNA (Bethesda category III, IV, and V), and 114 (57.0%) nodules were finally diagnosed as malignancy by surgery or core needle biopsy. The area under the curve (AUC) was higher for FNA than for either TIRADS system in all nodules, while all three methods showed similar AUCs for indeterminate nodules. However, for Bethesda category III nodules, applying K-TIRADS 5 significantly increased the risk of malignancy compared to a cytological examination alone (50.0% vs. 26.5%, P=0.028), whereas applying ACR-TIRADS did not lead to a change.
Conclusion
K-TIRADS and ACR-TIRADS showed similar diagnostic performance in assessing indeterminate thyroid nodules, and K-TIRADS had beneficial effects for malignancy prediction in Bethesda category III nodules.

Citations

Citations to this article as recorded by

Is the nodule location a predictive risk factor for cancer in AUS/FLUS thyroid nodules? A retrospective cohort study
Saad M. Alqahtani, Bassam A. Altalhi, Yousef S. Alalawi, Saif S. Al-Sobhi
Asian Journal of Surgery.2024;[Epub] CrossRef
Diagnostic Performance of Various Ultrasound Risk Stratification Systems for Benign and Malignant Thyroid Nodules: A Meta-Analysis
Ji-Sun Kim, Byung Guk Kim, Gulnaz Stybayeva, Se Hwan Hwang
Cancers.2023; 15(2): 424. CrossRef
The impact of thyroid imaging reporting and data system on the management of Bethesda III thyroid nodules
Saad M. Alqahtani, Saif S. Al-Sobhi, Mohammed A. Alturiqy, Riyadh I. Alsalloum, Hindi N. Al-Hindi
Journal of Taibah University Medical Sciences.2023; 18(3): 506. CrossRef
Diagnostic Performance of Six Ultrasound Risk Stratification Systems for Thyroid Nodules: A Systematic Review and Network Meta-Analysis
Do Hyun Kim, Sung Won Kim, Mohammed Abdullah Basurrah, Jueun Lee, Se Hwan Hwang
American Journal of Roentgenology.2023; 220(6): 791. CrossRef
Diagnostic efficiency among Eu-/C-/ACR-TIRADS and S-Detect for thyroid nodules: a systematic review and network meta-analysis
Longtao Yang, Cong Li, Zhe Chen, Shaqi He, Zhiyuan Wang, Jun Liu
Frontiers in Endocrinology.2023;[Epub] CrossRef
Comparison of diagnostic performance of two ultrasound risk stratification systems for thyroid nodules: a systematic review and meta-analysis
Yun Jin Kang, Hee Sun Ahn, Gulnaz Stybayeva, Ju Eun Lee, Se Hwan Hwang
La radiologia medica.2023; 128(11): 1407. CrossRef
Diagnostic Performance of ACR and Kwak TI-RADS for Benign and Malignant Thyroid Nodules: An Update Systematic Review and Meta-Analysis
Yun Jin Kang, Gulnaz Stybayeya, Ju Eun Lee, Se Hwan Hwang
Cancers.2022; 14(23): 5961. CrossRef
Comparison of Thyroid Imaging Reporting and Data Systems in Malignancy Risk Stratification of Indeterminate Thyroid Nodules
Bo Hyun Kim
Endocrinology and Metabolism.2021; 36(5): 974. CrossRef

Endocrine Research
DEHP Down-Regulates Tshr Gene Expression in Rat Thyroid Tissues and FRTL-5 Rat Thyrocytes: A Potential Mechanism of Thyroid Disruption: Min Joo Kim, Hwan Hee Kim, Young Shin Song, Ok-Hee Kim, Kyungho Choi, Sujin Kim, Byung-Chul Oh, Young Joo Park; Endocrinol Metab. 2021;36(2):447-454. Published online March 31, 2021; DOI: https://doi.org/10.3803/EnM.2020.920

5,083 View
145 Download
12 Web of Science
12 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Di-2-ethylhexyl phthalate (DEHP) is known to disrupt thyroid hormonal status. However, the underlying molecular mechanism of this disruption is unclear. Therefore, we investigated the direct effects of DEHP on the thyroid gland.
Methods
DEHP (vehicle, 50 mg/kg, and 500 mg/kg) was administered to Sprague-Dawley rats for 2 weeks. The expression of the thyroid hormone synthesis pathway in rat thyroid tissues was analyzed through RNA sequencing analysis, quantitative reverse transcription-polymerase chain reaction (RT-PCR), and immunohistochemical (IHC) staining. DEHP was treated to FRTL-5 rat thyroid cells, and an RT-PCR analysis was performed. A reporter gene assay containing the promoter of thyroid stimulating hormone receptor (TSHR) in Nthy-ori 3-1 human thyroid cells was constructed, and luciferase activity was determined.
Results
After DEHP treatment, the free thyroxine (T4) and total T4 levels in rats significantly decreased. RNA sequencing analysis of rat thyroid tissues showed little difference between vehicle and DEHP groups. In the RT-PCR analysis, Tshr expression was significantly lower in both DEHP groups (50 and 500 mg/kg) compared to that in the vehicle group, and IHC staining showed that TSHR expression in the 50 mg/kg DEHP group significantly decreased. DEHP treatment to FRTL-5 cells significantly down-regulated Tshr expression. DEHP treatment also reduced luciferase activity in a reporter gene assay for TSHR.
Conclusion
Although overall genetic changes in the thyroid hormone synthesis pathway are not clear, DEHP exposure could significantly down-regulate Tshr expression in thyroid glands. Down-regulation of Tshr gene appears to be one of potential mechanisms of thyroid disruption by DEHP exposure.

Citations

Citations to this article as recorded by

ARTS is essential for di-2-ethylhexyl phthalate (DEHP)-induced apoptosis of mouse Leydig cells
Yue Li, Linlin Xu, Chaoju Hao, Si Yang, Jinglei Wang, Jiaxiang Chen
Ecotoxicology and Environmental Safety.2024; 270: 115882. CrossRef
Thyroid dysfunction caused by exposure to environmental endocrine disruptors and the underlying mechanism: A review
Jie He, Jie Xu, Mucong Zheng, Kai Pan, Lilin Yang, Lina Ma, Chuyang Wang, Jie Yu
Chemico-Biological Interactions.2024; 391: 110909. CrossRef
Intrauterine exposure to di(2-ethylhexyl) phthalate (DEHP) disrupts the function of the hypothalamus-pituitary-thyroid axis of the F1 rats during adult life
Érica Kássia Sousa-Vidal, Guilherme Henrique, Renata Elen Costa da Silva, Caroline Serrano-Nascimento
Frontiers in Endocrinology.2023;[Epub] CrossRef
Drinking water disinfection byproduct iodoacetic acid affects thyroid hormone synthesis in Nthy-ori 3–1 cells
Jingyi Xiao, Yujie Sha, Yuwen Huang, Kunling Long, Huan Wu, Yan Mo, Qiyuan Yang, Shengkun Dong, Qiang Zeng, Xiao Wei
Ecotoxicology and Environmental Safety.2023; 257: 114926. CrossRef
Assessment of five typical environmental endocrine disruptors and thyroid cancer risk: a meta-analysis
Yuyao Yang, Xiaoyue Bai, Juan Lu, Ronghao Zou, Rui Ding, Xiaohui Hua
Frontiers in Endocrinology.2023;[Epub] CrossRef
Investigation of the effects of phthalates on in vitro thyroid models with RNA-Seq and ATAC-Seq
Marta Nazzari, Mírian Romitti, Duncan Hauser, Daniel J. Carvalho, Stefan Giselbrecht, Lorenzo Moroni, Sabine Costagliola, Florian Caiment
Frontiers in Endocrinology.2023;[Epub] CrossRef
Di(2-ethylhexyl) phthalate (DEHP) and thyroid: biological mechanisms of interference and possible clinical implications
Xueting Zhang, Wen Qi, Qi Xu, Xu Li, Liting Zhou, Lin Ye
Environmental Science and Pollution Research.2022; 29(2): 1634. CrossRef
The possible thyroid disruptive effect of di-(2-ethyl hexyl) phthalate and the potential protective role of selenium and curcumin nanoparticles: a toxicological and histological study
Naima Abd El-Halim Sherif, Asmaa El-Banna, Rehab Ahmed Abdel-Moneim, Zahraa Khalifa Sobh, Manal Ibrahim Fathy Balah
Toxicology Research.2022; 11(1): 108. CrossRef
Environmental disruption of reproductive rhythms
Marie-Azélie Moralia, Clarisse Quignon, Marine Simonneaux, Valérie Simonneaux
Frontiers in Neuroendocrinology.2022; 66: 100990. CrossRef
Endocrine-disruptor endpoints in the ovary and thyroid of adult female rats exposed to realistic doses of di-(2-ethylhexyl) phthalate
Amel Jebara, Asma Beltifa, Guissepa Di Bella, Lotfi Mabrouk, Hedi Ben Mansour
Journal of Water and Health.2022; 20(8): 1256. CrossRef
The influence of sunitinib and sorafenib, two tyrosine kinase inhibitors, on development and thyroid system in zebrafish larvae
Gang Wei, Cao-xu Zhang, Yu Jing, Xia Chen, Huai-dong Song, Liu Yang
Chemosphere.2022; 308: 136354. CrossRef
Role of estrogen receptors in thyroid toxicity induced by mono (2-ethylhexyl) phthalate via endoplasmic reticulum stress: An in vitro mechanistic investigation
Qi Xu, Liting Zhou, Hyonju Ri, Xu Li, Xueting Zhang, Wen Qi, Lin Ye
Environmental Toxicology and Pharmacology.2022; 96: 104007. CrossRef

Clinical Study
Romosozumab in Postmenopausal Korean Women with Osteoporosis: A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study: Ki-Hyun Baek, Yoon-Sok Chung, Jung-Min Koh, In Joo Kim, Kyoung Min Kim, Yong-Ki Min, Ki Deok Park, Rajani Dinavahi, Judy Maddox, Wenjing Yang, Sooa Kim, Sang Jin Lee, Hyungjin Cho, Sung-Kil Lim; Endocrinol Metab. 2021;36(1):60-69. Published online February 24, 2021; DOI: https://doi.org/10.3803/EnM.2020.848

6,823 View
390 Download
7 Web of Science
10 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
This phase 3 study evaluated the efficacy and safety of 6-month treatment with romosozumab in Korean postmenopausal women with osteoporosis.
Methods
Sixty-seven postmenopausal women with osteoporosis (bone mineral density [BMD] T-scores ≤–2.5 at the lumbar spine, total hip, or femoral neck) were randomized (1:1) to receive monthly subcutaneous injections of romosozumab (210 mg; n=34) or placebo (n=33) for 6 months.
Results
At month 6, the difference in the least square (LS) mean percent change from baseline in lumbar spine BMD (primary efficacy endpoint) between the romosozumab (9.5%) and placebo (–0.1%) groups was significant (9.6%; 95% confidence interval, 7.6 to 11.5; P<0.001). The difference in the LS mean percent change from baseline was also significant for total hip and femoral neck BMD (secondary efficacy endpoints). After treatment with romosozumab, the percent change from baseline in procollagen type 1 N-terminal propeptide transiently increased at months 1 and 3, while that in C-terminal telopeptide of type 1 collagen showed a sustained decrease. No events of cancer, hypocalcemia, injection site reaction, positively adjudicated atypical femoral fracture or osteonecrosis of the jaw, or positively adjudicated serious cardiovascular adverse events were observed. At month 9, 17.6% and 2.9% of patients in the romosozumab group developed binding and neutralizing antibodies, respectively.
Conclusion
Treatment with romosozumab for 6 months was well tolerated and significantly increased lumbar spine, total hip, and femoral neck BMD compared with placebo in Korean postmenopausal women with osteoporosis (ClinicalTrials.gov identifier NCT02791516).

Citations

Citations to this article as recorded by

A pharmacovigilance analysis of FDA adverse event reporting system events for romosozumab
Zepeng Chen, Ming Li, Shuzhen Li, Yuxi Li, Junyan Wu, Kaifeng Qiu, Xiaoxia Yu, Lin Huang, Guanghui Chen
Expert Opinion on Drug Safety.2023; 22(4): 339. CrossRef
Evaluation of the efficacy and safety of romosozumab (evenity) for the treatment of osteoporotic vertebral compression fracture in postmenopausal women: A systematic review and meta‐analysis of randomized controlled trials (CDM‐J)
Wenbo Huang, Masashi Nagao, Naohiro Yonemoto, Sen Guo, Takeshi Tanigawa, Yuji Nishizaki
Pharmacoepidemiology and Drug Safety.2023; 32(6): 671. CrossRef
Efficacy and Cardiovascular Safety of Romosozumab: A Meta-analysis and Systematic Review
Seo-Yong Choi, Jeong-Min Kim, Sang-Hyeon Oh, Seunghyun Cheon, Jee-Eun Chung
Korean Journal of Clinical Pharmacy.2023; 33(2): 128. CrossRef
Clinical Studies On Romosozumab: An Alternative For Individuals With A High Risk Of Osteoporotic Fractures: A Current Concepts Review (Part I)
E. Carlos Rodriguez-Merchan, Alonso Moreno-Garcia, Hortensia De la Corte-Rodriguez
SurgiColl.2023;[Epub] CrossRef
Romosozumab in osteoporosis: yesterday, today and tomorrow
Dong Wu, Lei Li, Zhun Wen, Guangbin Wang
Journal of Translational Medicine.2023;[Epub] CrossRef
Efficacy and safety of anti-sclerostin antibodies in the treatment of osteoporosis: A meta-analysis and systematic review
Frideriki Poutoglidou, Efthimios Samoladas, Nikolaos Raikos, Dimitrios Kouvelas
Journal of Clinical Densitometry.2022; 25(3): 401. CrossRef
Benefits of lumican on human bone health: clinical evidence using bone marrow aspirates
Yun Sun Lee, So Jeong Park, Jin Young Lee, Eunah Choi, Beom-Jun Kim
The Korean Journal of Internal Medicine.2022; 37(4): 821. CrossRef
What is the risk of cardiovascular events in osteoporotic patients treated with romosozumab?
I. R. Reid
Expert Opinion on Drug Safety.2022; 21(12): 1441. CrossRef
Proxied Therapeutic Inhibition on Wnt Signaling Antagonists and Risk of Cardiovascular Diseases: Multi-Omics Analyses
Yu Qian, Cheng-Da Yuan, Saber Khederzadeh, Ming-Yu Han, Hai-Xia Liu, Mo-Chang Qiu, Jian-Hua Gao, Wei-Lin Wang, Yun-Piao Hou, Guo-Bo Chen, Ke-Qi Liu, Lin Xu, David Karasik, Shu-Yang Xie, Hou-Feng Zheng
SSRN Electronic Journal .2022;[Epub] CrossRef
Multi-Omics Analyses Identify Pleiotropy and Causality Between Circulating Sclerostin and Atrial Fibrillation
Yu Qian, Peng-Lin Guan, Saber Khederzadeh, Ke-Qi Liu, Cheng-Da Yuan, Ming-Yu Han, Hai-Xia Liu, Mo-Chang Qiu, Jian-Hua Gao, Wei-Lin Wang, Yun-Piao Hou, Guo-Bo Chen, Lin Xu, David Karasik, Shu-Yang Xie, sheng zhifeng, Hou-Feng Zheng
SSRN Electronic Journal .2022;[Epub] CrossRef

Clinical Study
Vandetanib for the Management of Advanced Medullary Thyroid Cancer: A Real-World Multicenter Experience: Mijin Kim, Jee Hee Yoon, Jonghwa Ahn, Min Ji Jeon, Hee Kyung Kim, Dong Jun Lim, Ho-Cheol Kang, In Joo Kim, Young Kee Shong, Tae Yong Kim, Bo Hyun Kim; Endocrinol Metab. 2020;35(3):587-594. Published online September 22, 2020; DOI: https://doi.org/10.3803/EnM.2020.687

5,659 View
147 Download
12 Web of Science
12 Crossref

Abstract PDF PubReader ePub

Background
Vandetanib is the most widely used tyrosine kinase inhibitor for the treatment of patients with advanced medullary thyroid cancer (MTC). However, only limited data regarding its use outside clinical trials are available. We aimed to evaluate the efficacy and safety of vandetanib in patients with advanced MTC in routine clinical practice.
Methods
In this multicenter retrospective study, 12 patients with locally advanced or metastatic MTC treated with vandetanib at four tertiary hospitals were included. The primary outcome was the objective response rate (ORR) based on the Response Evaluation Criteria in Solid Tumors. The progression-free survival (PFS), overall survival (OS), and toxicities were also evaluated.
Results
Eleven patients (92%) had distant metastasis and 10 (83%) had disease progression at enrollment. Partial response was observed in five patients (ORR, 42%) and stable disease lasting ≥24 weeks was reported in an additional five patients (83%). During the median 31.7 months of follow-up, disease progression was seen in five patients (42%); of these, two died due to disease progression. The median PFS was 25.9 months, while the median OS was not reached. All patients experienced adverse events (AEs) which were generally consistent with the known safety profile of vandetanib. Vandetanib was discontinued in two patients due to skin toxicity.
Conclusion
Consistent with the phase III trial, this study confirmed the efficacy of vandetanib for advanced MTC in terms of both ORR and PFS in the real-world setting. Vandetanib was well tolerated in the majority of patients, and there were no fatal AEs.

Citations

Citations to this article as recorded by

Metastatic medullary thyroid carcinoma (MTC): disease course, treatment modalities and factors predisposing for drug resistance
Katerina Saltiki, George Simeakis, Olga Karapanou, Stavroula A. Paschou, Maria Alevizaki
Endocrine.2023; 80(3): 570. CrossRef
Initial Experiences of Selective RET Inhibitor Selpercatinib in Adults with Metastatic Differentiated Thyroid Carcinoma and Medullary Thyroid Carcinoma: Real-World Case Series in Korea
Han-Sang Baek, Jeonghoon Ha, Seunggyun Ha, Ja Seong Bae, Chan Kwon Jung, Dong-Jun Lim
Current Oncology.2023; 30(3): 3020. CrossRef
Molecular Basis and Natural History of Medullary Thyroid Cancer: It is (Almost) All in the RET
Nicolas Sahakian, Frédéric Castinetti, Pauline Romanet
Cancers.2023; 15(19): 4865. CrossRef
Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine
Antonio Matrone, Carla Gambale, Alessandro Prete, Rossella Elisei
Frontiers in Endocrinology.2022;[Epub] CrossRef
Targeted therapy and drug resistance in thyroid cancer
Yujie Zhang, Zhichao Xing, Tianyou Liu, Minghai Tang, Li Mi, Jingqiang Zhu, Wenshuang Wu, Tao Wei
European Journal of Medicinal Chemistry.2022; 238: 114500. CrossRef
Daily Management of Patients on Multikinase Inhibitors’ Treatment
Carla Colombo, Simone De Leo, Matteo Trevisan, Noemi Giancola, Anna Scaltrito, Laura Fugazzola
Frontiers in Oncology.2022;[Epub] CrossRef
The Angiogenic Balance and Its Implications in Cancer and Cardiovascular Diseases: An Overview
Cătălina Ionescu, Bogdan Oprea, Georgeta Ciobanu, Milena Georgescu, Ramona Bică, Garofiţa-Olivia Mateescu, Fidan Huseynova, Veronique Barragan-Montero
Medicina.2022; 58(7): 903. CrossRef
Reassessing vascular endothelial growth factor (VEGF) in anti-angiogenic cancer therapy
Tobiloba C. Elebiyo, Damilare Rotimi, Ikponmwosa O. Evbuomwan, Rotdelmwa Filibus Maimako, Matthew Iyobhebhe, Oluwafemi Adeleke Ojo, Olarewaju M. Oluba, Oluyomi S. Adeyemi
Cancer Treatment and Research Communications.2022; 32: 100620. CrossRef
Current Guidelines for Management of Medullary Thyroid Carcinoma
Mijin Kim, Bo Hyun Kim
Endocrinology and Metabolism.2021; 36(3): 514. CrossRef
Recent advances in precision medicine for the treatment of medullary thyroid cancer
Jolanta Krajewska, Aleksandra Kukulska, Malgorzata Oczko-Wojciechowska, Barbara Jarzab
Expert Review of Precision Medicine and Drug Development.2021; 6(5): 307. CrossRef
Functional evaluation of vandetanib metabolism by CYP3A4 variants and potential drug interactions in vitro
Mingming Han, Xiaodan Zhang, Zhize Ye, Jing Wang, Jianchang Qian, Guoxin Hu, Jianping Cai
Chemico-Biological Interactions.2021; 350: 109700. CrossRef
Nephrotoxicity in advanced thyroid cancer treated with tyrosine kinase inhibitors: An update
Alice Nervo, Francesca Retta, Alberto Ragni, Alessandro Piovesan, Alberto Mella, Luigi Biancone, Marco Manganaro, Marco Gallo, Emanuela Arvat
Critical Reviews in Oncology/Hematology.2021; 168: 103533. CrossRef

Clinical Study
Development and Validation of a Risk Scoring System Derived from Meta-Analyses of Papillary Thyroid Cancer: Sunghwan Suh, Tae Sik Goh, Yun Hak Kim, Sae-Ock Oh, Kyoungjune Pak, Ju Won Seok, In Joo Kim; Endocrinol Metab. 2020;35(2):435-442. Published online June 24, 2020; DOI: https://doi.org/10.3803/EnM.2020.35.2.435; Correction in: Endocrinol Metab 2023;38(2):287

5,574 View
130 Download
3 Web of Science
2 Crossref

Abstract PDF PubReader ePub

Background
The aim of this study was to develop a scoring system to stratify the risk of papillary thyroid cancer (PTC) and to select the proper management.
Methods
We performed a systematic search of MEDLINE and Embase. Data regarding patients’ prognoses were obtained from the included studies. Odds ratios (ORs) with statistical significance were extracted from the publications. To generate a risk scoring system (RSS), ORs were summed (RSS1), and summed after natural-logarithmic transformation (RSS2). RSS1 and RSS2 were compared to the eighth edition of the American Joint Committee on Cancer (AJCC) staging system and the 2015 American Thyroid Association (ATA) guidelines for thyroid nodules and differentiated thyroid carcinoma.
Results
Five meta-analyses were eligible for inclusion in the study. Eight variables (sex, tumour size, extrathyroidal extension, BRAF mutation, TERT mutation, histologic subtype, lymph node metastasis, and distant metastasis) were included. RSS1 was the best of the analysed models.
Conclusion
We developed and validated a new RSS derived from previous meta-analyses for patients with PTC. This RSS seems to be superior to previously published systems.

Citations

Citations to this article as recorded by

Investigating 18F-FDG PET/CT Parameters as Prognostic Markers for Differentiated Thyroid Cancer: A Systematic Review
Hongxi Wang, Hongyuan Dai, Qianrui Li, Guohua Shen, Lei Shi, Rong Tian
Frontiers in Oncology.2021;[Epub] CrossRef
Impact of Multifocality on the Recurrence of Papillary Thyroid Carcinoma
Joohyun Woo, Hyeonkyeong Kim, Hyungju Kwon
Journal of Clinical Medicine.2021; 10(21): 5144. CrossRef

Clinical Study
Low Predictive Value of FRAX Adjusted by Trabecular Bone Score for Osteoporotic Fractures in Korean Women: A Community-Based Cohort Study: Hana Kim, Jung Hee Kim, Min Joo Kim, A Ram Hong, HyungJin Choi, EuJeong Ku, Ji Hyun Lee, Chan Soo Shin, Nam H. Cho; Endocrinol Metab. 2020;35(2):359-366. Published online June 24, 2020; DOI: https://doi.org/10.3803/EnM.2020.35.2.359

5,967 View
132 Download
9 Web of Science
10 Crossref

Abstract PDF PubReader ePub

Background
The value of the Fracture Risk Assessment Tool (FRAX) and the trabecular bone score (TBS) for assessing osteoporotic fracture risk has not been fully elucidated in Koreans. We conducted this study to clarify the predictive value of FRAX adjusted by TBS for osteoporotic fractures in Korean women.
Methods
After screening 7,192 eligible subjects from the Ansung cohort, 1,165 women aged 45 to 76 years with available bone mineral density (BMD) and TBS data were enrolled in this study. We assessed their clinical risk factors for osteoporotic fractures and evaluated the predictive value of FRAX with or without BMD and TBS.
Results
During the mean follow-up period of 7.5 years, 99 (8.5%) women suffered major osteoporotic fractures (MOFs) and 28 (2.4%) experienced hip fractures. FRAX without BMD, BMD-adjusted FRAX, and TBS-adjusted FRAX were significantly associated with the risk of MOFs (hazard ratio [HR] per percent increase, 1.08; 95% confidence interval [CI], 1.03 to 1.14; HR, 1.09; 95% CI, 1.03 to 1.15; and HR, 1.07; 95% CI, 1.02 to 1.13, respectively). However, BMD-adjusted FRAX and TBS-adjusted FRAX did not predict MOFs better than FRAX without BMD based on the Harrell’s C statistic. FRAX probabilities showed limited value for predicting hip fractures. The cut-off values of FRAX without BMD, FRAX with BMD, and FRAX with BMD adjusted by TBS for predicting MOFs were 7.2%, 5.0%, and 6.7%, respectively.
Conclusion
FRAX with BMD and TBS adjustment did not show better predictive value for osteoporotic fractures in this study than FRAX without adjustment. Moreover, the cut-off values of FRAX probabilities for treatment might be lower in Korean women than in other countries.

Citations

Citations to this article as recorded by

Update on the utility of trabecular bone score (TBS) in clinical practice for the management of osteoporosis: a systematic review by the Egyptian Academy of Bone and Muscle Health
Yasser El Miedany, Walaa Elwakil, Mohammed Hassan Abu-Zaid, Safaa Mahran
Egyptian Rheumatology and Rehabilitation.2024;[Epub] CrossRef
Comparison of predictive value of FRAX, trabecular bone score, and bone mineral density for vertebral fractures in systemic sclerosis: A cross-sectional study
Kyung-Ann Lee, Hyun-Joo Kim, Hyun-Sook Kim
Medicine.2023; 102(2): e32580. CrossRef
Screening for the primary prevention of fragility fractures among adults aged 40 years and older in primary care: systematic reviews of the effects and acceptability of screening and treatment, and the accuracy of risk prediction tools
Michelle Gates, Jennifer Pillay, Megan Nuspl, Aireen Wingert, Ben Vandermeer, Lisa Hartling
Systematic Reviews.2023;[Epub] CrossRef
Chronic airway disease as a major risk factor for fractures in osteopenic women: Nationwide cohort study
Sung Hye Kong, Ae Jeong Jo, Chan Mi Park, Kyun Ik Park, Ji Eun Yun, Jung Hee Kim
Frontiers in Endocrinology.2023;[Epub] CrossRef
Update on the clinical use of trabecular bone score (TBS) in the management of osteoporosis: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Disease
Enisa Shevroja, Jean-Yves Reginster, Olivier Lamy, Nasser Al-Daghri, Manju Chandran, Anne-Laurence Demoux-Baiada, Lynn Kohlmeier, Marie-Paule Lecart, Daniel Messina, Bruno Muzzi Camargos, Juraj Payer, Sansin Tuzun, Nicola Veronese, Cyrus Cooper, Eugene V.
Osteoporosis International.2023; 34(9): 1501. CrossRef
Comparison of HU histogram analysis and BMD for proximal femoral fragility fracture assessment: a retrospective single-center case–control study
Sun-Young Park, Hong Il Ha, Injae Lee, Hyun Kyung Lim
European Radiology.2022; 32(3): 1448. CrossRef
Association of Trabecular Bone Score-Adjusted Fracture Risk Assessment Tool with Coronary Artery Calcification in Women
Tzyy-Ling Chuang, Yuh-Feng Wang, Malcolm Koo, Mei-Hua Chuang
Diagnostics.2022; 12(1): 178. CrossRef
Risk of osteoporotic fracture in women using the FRAX tool with and without bone mineral density score in patients followed at a tertiary outpatient clinic ‒ An observational study
Maria Helena Sampaio Favarato, Maria Flora de Almeida, Arnaldo Lichtenstein, Milton de Arruda Martins, Mario Ferreira Junior
Clinics.2022; 77: 100015. CrossRef
Comparison of Trabecular Bone Score–Adjusted Fracture Risk Assessment (TBS-FRAX) and FRAX Tools for Identification of High Fracture Risk among Taiwanese Adults Aged 50 to 90 Years with or without Prediabetes and Diabetes
Tzyy-Ling Chuang, Mei-Hua Chuang, Yuh-Feng Wang, Malcolm Koo
Medicina.2022; 58(12): 1766. CrossRef
Application of the Trabecular Bone Score in Clinical Practice
Sung Hye Kong, Namki Hong, Jin-Woo Kim, Deog Yoon Kim, Jung Hee Kim
Journal of Bone Metabolism.2021; 28(2): 101. CrossRef

Clinical Study
Association between Serum Free Thyroxine and Anemia in Euthyroid Adults: A Nationwide Study: Mijin Kim, Bo Hyun Kim, Hyungi Lee, Min Hee Jang, Jeong Mi Kim, Eun Heui Kim, Yun Kyung Jeon, Sang Soo Kim, In Joo Kim; Endocrinol Metab. 2020;35(1):106-114. Published online March 19, 2020; DOI: https://doi.org/10.3803/EnM.2020.35.1.106

6,137 View
120 Download
4 Web of Science
5 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background

Studies on the relationship between thyroid function and anemia in the euthyroid range are scarce. We aimed to evaluate the association between anemia and serum free thyroxine (fT4) and thyrotropin (TSH) in euthyroid adults.

Methods

Data on 5,352 participants aged ≥19 years were obtained from the Korea National Health and Nutrition Examination Survey VI (2013 to 2015). Anemia was defined as hemoglobin (Hb) <13 and <12 g/dL for men and women, respectively.

Results

Overall, 6.1% of participants had anemia, and more women (9.9%) had anemia than men (2.8%, P<0.001). In multivariate analysis, serum fT4 levels, but not TSH, were positively associated with serum Hb levels in both sexes (P<0.001, each). Serum Hb levels linearly reduced across decreasing serum fT4 quartile groups in both sexes (P<0.001, each). After adjusting for potential confounding factors, participants with low-normal fT4 had 4.4 (P=0.003) and 2.8 times (P<0.001) higher risk for anemia than those with high-normal fT4 among men and women, respectively. When participants were divided into two groups at 50 years of age, in younger participants, men and women with the first quartile were at higher risk of anemia than men with the second quartile (odds ratio [OR], 3.3; P=0.029) and women with the forth quartile (OR, 3.2; P<0.001), respectively. This association was not observed in older participants.

Conclusion

These results suggest that a low-normal level of serum fT4 was associated with a lower serum Hb level and a higher risk of anemia in euthyroid adults, especially in younger participants.

Citations

Citations to this article as recorded by

Thyroid Function and Risk of Anemia: A Multivariable-Adjusted and Mendelian Randomization Analysis in the UK Biobank
Nicolien A van Vliet, Annelies E P Kamphuis, Wendy P J den Elzen, Gerard J Blauw, Jacobijn Gussekloo, Raymond Noordam, Diana van Heemst
The Journal of Clinical Endocrinology & Metabolism.2022; 107(2): e643. CrossRef
Thyroid function, pernicious anemia and erythropoiesis: a two-sample Mendelian randomization study
Alisa D Kjaergaard, Alexander Teumer, Eirini Marouli, Panos Deloukas, Aleksander Kuś, Rosalie Sterenborg, Bjørn O Åsvold, Marco Medici, Christina Ellervik
Human Molecular Genetics.2022; 31(15): 2548. CrossRef
Changes of hematological indices in patients with diffuse toxic goiter
F. H. Saidova, L. M. Ahmedova, Zh. B. Aslanova, N. A. Najafov
Klinicheskaia khirurgiia.2021; 88(3-4): 76. CrossRef
Association between Serum Free Thyroxine and Anemia in Euthyroid Adults: A Nationwide Study (Endocrinol Metab 2020;35:106-14, Mijin Kim et al.)
Zheng Feei Ma
Endocrinology and Metabolism.2020; 35(2): 484. CrossRef
Association between Serum Free Thyroxine and Anemia in Euthyroid Adults: A Nationwide Study (Endocrinol Metab 2020;35:106-14, Mijin Kim et al.)
Mijin Kim, Bo Hyun Kim
Endocrinology and Metabolism.2020; 35(3): 669. CrossRef

Review Article

Thyroid
Bisphenols and Thyroid Hormone: Min Joo Kim, Young Joo Park; Endocrinol Metab. 2019;34(4):340-348. Published online December 23, 2019; DOI: https://doi.org/10.3803/EnM.2019.34.4.340

9,123 View
235 Download
60 Web of Science
64 Crossref

Abstract PDF PubReader ePub

In recent decades, attention has been directed toward the effects of bisphenol A (BPA) on human health. BPA has estrogenic activity and is regarded as a representative endocrine disruptor. In addition, mounting evidence indicates that BPA can disrupt thyroid hormone and its action. This review examined human epidemiological studies to investigate the association between BPA exposure and thyroid hormone levels, and analyzed in vivo and in vitro experiments to identify the causal relationship and its mechanism of action. BPA is involved in thyroid hormone action not only as a thyroid hormone receptor antagonist, but also through several other mechanisms. Since the use of bisphenols other than BPA has recently increased, we also reviewed the effects of other bisphenols on thyroid hormone action.

Citations

Citations to this article as recorded by

The Role of Endocrine Disruptors Bisphenols and Phthalates in Obesity: Current Evidence, Perspectives and Controversies
Maria Dalamaga, Dimitrios Kounatidis, Dimitrios Tsilingiris, Natalia G. Vallianou, Irene Karampela, Sotiria Psallida, Athanasios G. Papavassiliou
International Journal of Molecular Sciences.2024; 25(1): 675. CrossRef
Environmental toxicology of bisphenol A: Mechanistic insights and clinical implications on the neuroendocrine system
Tongbing Qi, Dongqing Jing, Kexin Zhang, Junfeng Shi, Hongyan Qiu, Chengxia Kan, Fang Han, Chunyan Wu, Xiaodong Sun
Behavioural Brain Research.2024; 460: 114840. CrossRef
Antioxidant compounds from the Arthrospira platensis protect against Bisphenol A-induced nephrotoxicity in rats
Khadidja Chouala, Kahina Boudjema, Yahia Khelef, Sadok Nani, Kheireddine Ouali, Mahieddine Boumendjel, Amel Boumendjel, Mahfoud Messarah
Toxicology and Environmental Health Sciences.2024; 16(1): 75. CrossRef
Associations of urinary non-persistent endocrine disrupting chemical biomarkers with early-to-mid pregnancy plasma sex-steroid and thyroid hormones
Brad A. Ryva, Diana C. Pacyga, Kaitlyn Y. Anderson, Antonia M. Calafat, Jason Whalen, Max T. Aung, Joseph C. Gardiner, Joseph M. Braun, Susan L. Schantz, Rita S. Strakovsky
Environment International.2024; 183: 108433. CrossRef
Prospective role of lusianthridin in attenuating cadmium-induced functional and cellular damage in rat thyroid
Teng Gao, Sijia Luo, Hongguang Li, Zijie Su, Qinghui Wen
Heliyon.2024; 10(5): e27080. CrossRef
Exposure to Bisphenol A, S, and F and its Association with Obesity and Diabetes Mellitus in General Adults of Korea: Korean National Environmental Health Survey (KoNEHS) 2015–2017
Min Kyong Moon, Min Joo Kim, Inae Lee, Sunmi Kim, Sohyeon Choi, Jeongim Park, Yoon Hee Cho, Sooyeon Hong, Jiyoung Yoo, Hyunwoong Park, Gi Jeong Cheon, Young Joo Park, Kyungho Choi
Exposure and Health.2023; 15(1): 53. CrossRef
Exposure to Bisphenol A increases malignancy risk of thyroid nodules in overweight/obese patients
Vincenzo Marotta, Lucia Grumetto, Ilaria Neri, Giacomo Russo, Anna Tortora, Giulia Izzo, Ilaria Panariello, Domenico Rocco, Luciano Pezzullo, Mario Vitale
Environmental Pollution.2023; 316: 120478. CrossRef
A case-control study of urinary concentrations of bisphenol A, bisphenol F, and bisphenol S and the risk of papillary thyroid cancer
Lei Zhang, Jiahuai Zhang, Sai Fan, Yuxin Zhong, Jingguang Li, Yunfeng Zhao, Song Ni, Jiaying Liu, Yongning Wu
Chemosphere.2023; 312: 137162. CrossRef
Endocrine disruptors and endometriosis
Sudipta Dutta, Sakhila K. Banu, Joe A. Arosh
Reproductive Toxicology.2023; 115: 56. CrossRef
Bisphenol A alternatives continuously contribute to the endocrine disruption in cetaceans
Yongwei Guo, Wei Shi, Zhiwei Liu, Xian Sun, Jiaxue Wu, Yuping Wu
Environment International.2023; 171: 107679. CrossRef
Environmental endocrine disruptors and amphibian immunity: A bridge between the thyroid hormone axis and T cell development
Connor C. McGuire, Jacques R. Robert
Developmental & Comparative Immunology.2023; 140: 104617. CrossRef
Transient developmental exposure to low doses of bisphenol F negatively affects neurogliogenesis and olfactory behaviour in adult mice
Pieter Vancamp, Lucile Butruille, Anni Herranen, Anita Boelen, Jean-Baptiste Fini, Barbara A. Demeneix, Sylvie Remaud
Environment International.2023; 172: 107770. CrossRef
A Fast Method for Determination of Seven Bisphenols in Human Breast Milk Samples with the Use of HPLC-FLD
Szymon Szubartowski, Tomasz Tuzimski
Molecules.2023; 28(3): 1432. CrossRef
Risk Assessment of Bisphenol A in the Korean General Population
Myungsil Hwang, Seon-Joo Park, Hae-Jeung Lee
Applied Sciences.2023; 13(6): 3587. CrossRef
Current Evidence on Bisphenol A Exposure and the Molecular Mechanism Involved in Related Pathological Conditions
Ylenia Della Rocca, Enrico Matteo Traini, Francesca Diomede, Luigia Fonticoli, Oriana Trubiani, Alessia Paganelli, Jacopo Pizzicannella, Guya Diletta Marconi
Pharmaceutics.2023; 15(3): 908. CrossRef
The associations between concentrations of gestational bisphenol analogues and thyroid related hormones in cord blood: A prospective cohort study
Jianya Xi, Xiujuan Su, Ziliang Wang, Honglei Ji, Yao Chen, Xiaofang Liu, Maohua Miao, Hong Liang, Wei Yuan
Ecotoxicology and Environmental Safety.2023; 256: 114838. CrossRef
Zebrafish (Danio rerio) TRβ- and TTR-based electrochemical biosensors: Construction and application for the evaluation of thyroid-disrupting activity of bisphenols
Yuejiao Li, Zhenzhong Zhang, Jun Wang, Yeqi Shan, Hua Tian, Pengfei Cui, Shaoguo Ru
Environmental Pollution.2023; 330: 121745. CrossRef
Iodine Deficiency, Maternal Hypothyroxinemia and Endocrine Disrupters Affecting Fetal Brain Development: A Scoping Review
Rolf Grossklaus, Klaus-Peter Liesenkötter, Klaus Doubek, Henry Völzke, Roland Gaertner
Nutrients.2023; 15(10): 2249. CrossRef
Bisphenol A Analogues Inhibit Human and Rat 11β-Hydroxysteroid Dehydrogenase 1 Depending on Its Lipophilicity
Hong Wang, Jianmin Sang, Zhongyao Ji, Yang Yu, Shaowei Wang, Yang Zhu, Huitao Li, Yiyan Wang, Qiqi Zhu, Renshan Ge
Molecules.2023; 28(13): 4894. CrossRef
Bisphenol A-Induced Endocrine Dysfunction and its Associated Metabolic Disorders
Meenu Maniradhan, Latchoumycandane Calivarathan
Endocrine, Metabolic & Immune Disorders - Drug Targets.2023; 23(4): 515. CrossRef
Origin, dietary exposure, and toxicity of endocrine-disrupting food chemical contaminants: A comprehensive review
Leila Peivasteh-roudsari, Raziyeh Barzegar-bafrouei, Kurush Aghbolagh Sharifi, Shamimeh Azimisalim, Marziyeh Karami, Solmaz Abedinzadeh, Shabnam Asadinezhad, Behrouz Tajdar-oranj, Vahideh Mahdavi, Adel Mirza Alizadeh, Parisa Sadighara, Margherita Ferrante
Heliyon.2023; 9(7): e18140. CrossRef
Bisphenol analogues induce thyroid dysfunction via the disruption of the thyroid hormone synthesis pathway
Chao Hu, Yeqing Xu, Mingmin Wang, Shixuan Cui, Hangjun Zhang, Liping Lu
Science of The Total Environment.2023; 900: 165711. CrossRef
Distinct inhibitory strength of bisphenol A analogues on human and rat 11β-hydroxysteroid dehydrogenase 1: 3D quantitative structure-activity relationship and in silico molecular docking analysis
Han Lu, Shaowei Wang, Jingyi Zheng, Yang Zhu, Yiyan Wang, Huitao Li, Ren-shan Ge
Ecotoxicology and Environmental Safety.2023; 267: 115638. CrossRef
Systematic Review on Safety of Bisphenol A: from Invention to the Present
Hananeh KORDBACHEH, Bensu KARAHALİL
Eurasian Journal of Toxicology.2023; 5(2): 37. CrossRef
Bisphenol S dysregulates thyroid hormone homeostasis; Testicular survival, redox and metabolic status: Ameliorative actions of melatonin
Aishwarya Sahu, Rakesh Verma
Environmental Toxicology and Pharmacology.2023; 104: 104300. CrossRef
Structural binding perspectives of common plasticizers and a flame retardant, BDE‐153, against thyroxine‐binding globulin: potential for endocrine disruption
Ishfaq Ahmad Sheikh, Mohd Amin Beg
Journal of Applied Toxicology.2022; 42(5): 841. CrossRef
New insights on the effects of endocrine-disrupting chemicals on children
Barbara Predieri, Crésio A.D. Alves, Lorenzo Iughetti
Jornal de Pediatria.2022; 98: S73. CrossRef
Toxic Metal Concentrations in Drinking Water and Possible Effect on Sex Hormones among Men in Sabongida-Ora, Edo State, Nigeria
Osaro Ogie Enehizena, Mathias A. Emokpae
Medicines.2022; 9(1): 4. CrossRef
Bisphenols impact hormone levels in animals: A meta-analysis
Alexander M. Rubin, Frank Seebacher
Science of The Total Environment.2022; 828: 154533. CrossRef
The effects of prenatal and lactational bisphenol A and/or di(2-ethylhexyl) phthalate exposure on female reproductive system
Gizem Ozkemahli, Aylin Balci Ozyurt, Pinar Erkekoglu, Naciye Dilara Zeybek, Nilgun Yersal, Belma Kocer-Gumusel
Toxicology Mechanisms and Methods.2022; 32(8): 597. CrossRef
Associations of Phthalate Metabolites and Bisphenol A Levels with Obesity in Children: The Korean National Environmental Health Survey (KoNEHS) 2015 to 2017
Moon Young Seo, Shinje Moon, Shin-Hye Kim, Mi Jung Park
Endocrinology and Metabolism.2022; 37(2): 249. CrossRef
Associations of bisphenol exposure with thyroid hormones in pregnant women: a prospective birth cohort study in China
Huishen Huang, Jun Liang, Peng Tang, Chuanxiang Yu, Haoran Fan, Qian Liao, Jinghua Long, Dongxiang Pan, Xiaoyun Zeng, Shun Liu, Dongping Huang, Xiaoqiang Qiu
Environmental Science and Pollution Research.2022; 29(58): 87170. CrossRef
Bisphenols A, F, S and AF trigger apoptosis and/or endoplasmic reticulum stress in human endometrial stromal cells
Ricardo Ferreira, Cristina Amaral, Georgina Correia-da-Silva, Marta Almada, Margarida Borges, Sara Cristina Cunha, José Oliveira Fernandes, Natércia Teixeira
Toxicology.2022; 478: 153282. CrossRef
Association between phenols and thyroid hormones: The role of iodothyronine deiodinase genes
Blanca Sarzo, Reem Abumallouh, Natalia Marín, Sabrina Llop, Andrea Beneito, Inmaculada Lopez-Flores, Nerea Ferrero, Amrit Kaur Sakhi, Ferran Ballester, Maria-Jose Lopez-Espinosa
Environmental Pollution.2022; 311: 119926. CrossRef
Bisphenol A as a Factor in the Mosaic of Autoimmunity
Zora Lazurova, Ivica Lazurova, Yehuda Shoenfeld
Endocrine, Metabolic & Immune Disorders - Drug Targets.2022; 22(7): 728. CrossRef
Zebrafish as an emerging tool for drug discovery and development for thyroid diseases
Poonam Yadav, Lopmudra P. Sarode, Ravinder Reddy Gaddam, Puneet Kumar, Jasvinder Singh Bhatti, Amit Khurana, Umashanker Navik
Fish & Shellfish Immunology.2022; 130: 53. CrossRef
Review of in silico studies dedicated to the nuclear receptor family: Therapeutic prospects and toxicological concerns
Asma Sellami, Manon Réau, Matthieu Montes, Nathalie Lagarde
Frontiers in Endocrinology.2022;[Epub] CrossRef
Use of high-resolution metabolomics to assess the biological perturbations associated with maternal exposure to Bisphenol A and Bisphenol F among pregnant African American women
Rachel Tchen, Youran Tan, Dana Boyd Barr, P. Barry Ryan, ViLinh Tran, Zhenjiang Li, Yi-Juan Hu, Alicia K. Smith, Dean P. Jones, Anne L. Dunlop, Donghai Liang
Environment International.2022; 169: 107530. CrossRef
Effects of bisphenol A on pancreas and thyroid gland of young and adult female Sprague Dawlеy rats
D. Yahia, H. Hamdy, D. A. Salem, S. Afifi
BULGARIAN JOURNAL OF VETERINARY MEDICINE.2022; 25(3): 426. CrossRef
Bisphenol A analogues induce a feed-forward estrogenic response in zebrafish
Silvia Karim, Ruixin Hao, Caroline Pinto, Jan-Åke Gustafsson, Marina Grimaldi, Patrick Balaguer, Maria Bondesson
Toxicology and Applied Pharmacology.2022; 455: 116263. CrossRef
Mediterranean Diet and Thyroid: An Interesting Alliance
Giuseppe Bellastella, Lorenzo Scappaticcio, Francesco Caiazzo, Maria Tomasuolo, Raffaela Carotenuto, Mariangela Caputo, Stefania Arena, Paola Caruso, Maria Ida Maiorino, Katherine Esposito
Nutrients.2022; 14(19): 4130. CrossRef
Endocrine Disrupting Chemicals’ Effects in Children: What We Know and What We Need to Learn?
Barbara Predieri, Lorenzo Iughetti, Sergio Bernasconi, Maria Elisabeth Street
International Journal of Molecular Sciences.2022; 23(19): 11899. CrossRef
Single and repeated bisphenol A treatment induces ROS, Aβ and hyperphosphorylated-tau accumulation, and insulin pathways disruption, through HDAC2 and PTP1B overexpression, leading to SN56 cholinergic apoptotic cell death
Andrea Flores, Paula Moyano, Emma Sola, José Manuel García, Jimena García, María José Anadon, María Teresa Frejo, Maria Victoria Naval, Maria de la Cabeza Fernadez, Javier del Pino
Food and Chemical Toxicology.2022; 170: 113500. CrossRef
Application of High-Performance Liquid Chromatography Combined with Fluorescence Detector and Dispersive Liquid–Liquid Microextraction to Quantification of Selected Bisphenols in Human Amniotic Fluid Samples
Szymon Szubartowski, Tomasz Tuzimski
International Journal of Environmental Research and Public Health.2022; 20(1): 297. CrossRef
The Association between Phenols and Thyroid Hormones: The Role of Iodothyronine Deiodinase Genes
Blanca Sarzo, Reem Abumallouh, Natalia Marin, Sabrina Llop, Andrea Beneito, Inmaculada Lopez-Flores, Nerea Ferrero, Amrit Kaur Sakhi, ferran ballester, Maria-Jose Lopez-Espinosa
SSRN Electronic Journal .2022;[Epub] CrossRef
Bisphenols emerging in Norwegian and Czech aquatic environments show transthyretin binding potency and other less-studied endocrine-disrupting activities
Pavel Šauer, Helena Švecová, Kateřina Grabicová, Farah Gönül Aydın, Tomáš Mackuľak, Vít Kodeš, Line Diana Blytt, Liv Bruås Henninge, Roman Grabic, Hana Kocour Kroupová
Science of The Total Environment.2021; 751: 141801. CrossRef
Endocrine Disrupting Chemicals and Thyroid Cancer: An Overview
Mathilda Alsen, Catherine Sinclair, Peter Cooke, Kimia Ziadkhanpour, Eric Genden, Maaike van Gerwen
Toxics.2021; 9(1): 14. CrossRef
Thyroid-Modulating Activities of Olive and Its Polyphenols: A Systematic Review
Kok-Lun Pang, Johanna Nathania Lumintang, Kok-Yong Chin
Nutrients.2021; 13(2): 529. CrossRef
Human biomonitoring of bisphenol A along pregnancy: An exposure reconstruction of the EXHES-Spain cohort
María Ángeles Martínez, Neus González, Anna Martí, Montse Marquès, Joaquim Rovira, Vikas Kumar, Martí Nadal
Environmental Research.2021; 196: 110941. CrossRef
Dietary Intake of Endocrine Disrupting Substances Presents in Environment and Their Impact on Thyroid Function
Aneta Sokal, Sara Jarmakiewicz-Czaja, Jacek Tabarkiewicz, Rafał Filip
Nutrients.2021; 13(3): 867. CrossRef
BPA and BPA alternatives BPS, BPAF, and TMBPF, induce cytotoxicity and apoptosis in rat and human stem cells
Kristen G. Harnett, Ashley Chin, Sonya M. Schuh
Ecotoxicology and Environmental Safety.2021; 216: 112210. CrossRef
Bisphenols and the Development of Type 2 Diabetes: The Role of the Skeletal Muscle and Adipose Tissue
Fozia Ahmed, Maria Pereira, Céline Aguer
Environments.2021; 8(4): 35. CrossRef
Involvement of Thyroid Hormones in Brain Development and Cancer
Gabriella Schiera, Carlo Maria Di Liegro, Italia Di Liegro
Cancers.2021; 13(11): 2693. CrossRef
Environmental Factors Affecting Thyroid-Stimulating Hormone and Thyroid Hormone Levels
Mirjana Babić Leko, Ivana Gunjača, Nikolina Pleić, Tatijana Zemunik
International Journal of Molecular Sciences.2021; 22(12): 6521. CrossRef
Thyroid health in big city realities
Liudmila L. Kamynina
City Healthcare.2021; 2(2): 84. CrossRef
Adverse effects of bisphenol B exposure on the thyroid and nervous system in early life stages of zebrafish
Qian Yang, Zhenzhu Zhu, Qin Liu, Lihong Chen
Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology.2021; 250: 109167. CrossRef
Teratogenicity and toxicity of the new BPA alternative TMBPF, and BPA, BPS, and BPAF in chick embryonic development
Kristen G. Harnett, Lucy G. Moore, Ashley Chin, Isabel C. Cohen, Rylee R. Lautrup, Sonya M. Schuh
Current Research in Toxicology.2021; 2: 399. CrossRef
A Review on the Occurrence, Exposure, and Health Impacts of Bisphenol A
Prince Sharma, Khushboo Sharma, Geetika Sharma, Pooja Chadha
Toxicology International.2021; : 337. CrossRef
Thyroxine-binding globulin, peripheral deiodinase activity, and thyroid autoantibody status in association of phthalates and phenolic compounds with thyroid hormones in adult population
Sohyeon Choi, Min Joo Kim, Young Joo Park, Sunmi Kim, Kyungho Choi, Gi Jeong Cheon, Yoon Hee Cho, Hye Li Jeon, Jiyoung Yoo, Jeongim Park
Environment International.2020; 140: 105783. CrossRef
Clinical expression of endocrine disruptors in children
Lorenzo Iughetti, Laura Lucaccioni, Maria E. Street, Sergio Bernasconi
Current Opinion in Pediatrics.2020; 32(4): 554. CrossRef
Combined effects of di (2-ethylhexyl) phthalate and bisphenol A on thyroid hormone homeostasis in adolescent female rats
Xuan Zhang, Yuejiao Zhao, Cheng Cheng, Liuli Li, Mingyang Xiao, Guopei Zhang, Xiaobo Lu
Environmental Science and Pollution Research.2020; 27(32): 40882. CrossRef
How microplastic components influence the immune system and impact on children health: Focus on cancer
Mariana Segovia‐Mendoza, Karen E. Nava‐Castro, Margarita I. Palacios‐Arreola, Claudia Garay‐Canales, Jorge Morales‐Montor
Birth Defects Research.2020; 112(17): 1341. CrossRef
Perinatal exposure to Bisphenol A disturbs the early differentiation of male germ cells
Romina Pagotto, Clarisa G. Santamaría, María Belén Harreguy, Julián Abud, María Laura Zenclussen, Laura Kass, Martina Crispo, Mónica M. Muñoz-de-Toro, Horacio A. Rodriguez, Mariela Bollati-Fogolín
Reproductive Toxicology.2020; 98: 117. CrossRef
Novel Biobased Furanic Diols as Potential Alternatives to BPA: Synthesis and Endocrine Activity Screening
Catherine A. Sutton, Alexander Polykarpov, Keimpe Jan van den Berg, Alexander Yahkind, Linda J. Lea, Dean C. Webster, Mukund P. Sibi
ACS Sustainable Chemistry & Engineering.2020; 8(51): 18824. CrossRef

Case Reports

A Case of Insulinoma Localized by Percutaneous Tracshepatic Portal Catheterization with Insulin Hormone Assay.: Byung Jin Kim, Jun Sang Lee, Kyung Seuk Lee, Byung Gyu Park, In Joo Kim, Yong Ki Kim; J Korean Endocr Soc. 1996;11(3):355-361. Published online November 7, 2019

1,026 View
21 Download

Abstract PDF: The diagnosis of insulinoma is made primarily by the detection of an inappropriately elevated serum insulin level in the presence of a low blood glucose level. The successful resection of insulin-secreting islet cell turnors is greatly facilitated by accurate preoperative localization. But, the modalities of ultrasonography, computer tomography, magnetic resonance imaging and selective arteriography often fail to detect insulinoma smaller than 1.5 cm in diameter. In this report, we describe a patient with an insulinoma successfully localized by percutaneous transhepatic portal vein sampling but not by abdominal ultrasonography, computer tomography and selective arteriography. Percutaneous transhepatic portal vein catheterization with insulin sampling showed sudden step-up of insulin concentrations near 6 cm from distal splenic vein. During operation, a 1×1.3cm sized tumor was found at the junction of body and tail of pancreas, so distal pancreatectomy was performed, We propose that preoperative percutaneous transhepatic portal vein catheterization with measurement of radioimmunoactive insulin concentration is a safe and reliable method and plays an important role to localize insulinoma that are considered occult after conventional diagnostic studies have been negative.

Two Cases of Tubereuloeis of the Thyroid Gland with Euthyroidism.: Jae Bok Lee, Seok Man Son, Kyoung Seog Lee, Yeong Tae Jeong, In Joo Kim, Yong Ki Kim; J Korean Endocr Soc. 1994;9(4):380-384. Published online November 6, 2019

1,278 View
23 Download

Abstract PDF: Tuberculosis of the thyroid gland is extremely rare with few cases reported in recent years. Tuberculosis may involve the thyroid gland in two main forms. The more common of theses is miliary spread to the thyroid as part of generalized dissemination and less commonly focal or caseous tuberculosis of the thyroid may occur, presenting as a nodule, as a thyroiditis, as a abscess, or as carcinoma like.We experienced two cases of tuberculosis of the thyroid gland presenting with palpable thyroid nodule in 26 year-old female and 65 year-old female patients. They have been clinically and biochemically euthyroid and their thyroid scans demonstrated a cold nodule at right thyroid gland. We found no evidence of tuberculosis elsewhere. The goiter was removed surgically and confirmed to be tuberculosis. They were medicated antituberculous agents after operation and followed up regulary out patient department.We report the cases of two patients with tuberculosis involving thyroid with reviews of literature.

First
Prev
Page of 4
Next
Last

Search